Peter H Howarth Selected Research

Inflammation (Inflammations)

1/2023	The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti-IL-5 Biologic Therapy.
11/2022	The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps.
10/2022	Measurement of Exhaled Volatile Organic Compounds as a Biomarker for Personalised Medicine: Assessment of Short-Term Repeatability in Severe Asthma.
10/2022	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma.
1/2022	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.
1/2022	Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.
1/2021	Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
1/2021	Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation.
11/2019	Small RNA Species and microRNA Profiles are Altered in Severe Asthma Nanovesicles from Broncho Alveolar Lavage and Associate with Impaired Lung Function and Inflammation.
1/2019	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter H Howarth Research Topics

Disease

65	Asthma (Bronchial Asthma) 04/2024 - 01/2002
25	Inflammation (Inflammations) 01/2023 - 08/2004
8	Airway Remodeling 10/2022 - 08/2004
5	Infections 07/2016 - 07/2010
4	Nasal Polyps (Nasal Polyp) 01/2023 - 01/2022
4	Rhinosinusitis 01/2023 - 01/2022
4	Virus Diseases (Viral Diseases) 01/2022 - 12/2009
4	Allergic Rhinitis 09/2011 - 10/2004
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 08/2004
2	Eosinophilia 11/2022 - 01/2021
2	Necrosis 01/2016 - 07/2013
2	Atopic Dermatitis (Atopic Eczema) 10/2013 - 12/2009
1	Arthralgia (Joint Pain) 11/2022
1	Headache (Headaches) 11/2022
1	Eczema 01/2022
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2022
1	Sinusitis 01/2022
1	Disease Progression 01/2022
1	Churg-Strauss Syndrome (Allergic Angiitis) 01/2022
1	COVID-19 01/2020
1	Bacterial Infections (Bacterial Infection) 01/2018
1	Hyperplasia 12/2017
1	Respiratory Hypersensitivity 12/2017
1	Hypersensitivity (Allergy) 03/2016
1	Lung Diseases (Lung Disease) 01/2016
1	Polyps 01/2016

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 04/2024 - 02/2012
11	AllergensIBA 07/2016 - 12/2009
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2005
9	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2024 - 03/2006
9	SteroidsIBA 01/2022 - 03/2005
8	CytokinesIBA 10/2022 - 08/2004
8	Messenger RNA (mRNA)IBA 01/2020 - 05/2005
7	Interleukin-6 (Interleukin 6)IBA 11/2019 - 05/2011
6	mepolizumabIBA 01/2023 - 05/2018
6	Interleukin-5 (Interleukin 5)IBA 01/2023 - 01/2016
6	Interleukin-13IBA 01/2022 - 08/2011
6	DisintegrinsIBA 07/2016 - 05/2005
6	InterferonsIBA 03/2016 - 07/2010
5	Metalloproteases (Metalloproteinases)IBA 07/2016 - 05/2005
4	MicroRNAs (MicroRNA)IBA 11/2019 - 01/2014
4	AntioxidantsIBA 01/2018 - 08/2002
3	InterleukinsIBA 11/2022 - 01/2019
3	PeriostinIBA 01/2021 - 01/2018
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 07/2013
3	Antiviral Agents (Antivirals)IBA 01/2016 - 07/2010
3	LigandsIBA 07/2013 - 01/2002
3	Albuterol (Salbutamol)FDA LinkGeneric 10/2012 - 01/2011
2	Omalizumab (Xolair)FDA Link 04/2024 - 01/2022
2	Interleukin-4 (Interleukin 4)IBA 10/2022 - 01/2019
2	dupilumabIBA 01/2022 - 01/2022
2	Protein Isoforms (Isoforms)IBA 01/2020 - 01/2018
2	RNA (Ribonucleic Acid)IBA 11/2019 - 07/2010
2	MucinsIBA 01/2019 - 01/2018
2	Immunoglobulin E (IgE)IBA 01/2019 - 12/2009
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 01/2018
2	EnzymesIBA 01/2018 - 01/2016
2	hydroxyethyl methacrylate (HEMA)IBA 11/2016 - 09/2011
2	Chemokine CCL5IBA 03/2016 - 05/2011
2	Interleukin-8 (Interleukin 8)IBA 01/2016 - 01/2014
2	OvalbuminIBA 07/2013 - 08/2011
2	ChemokinesIBA 07/2013 - 08/2004
2	Methacholine Chloride (Methacholine)FDA Link 10/2012 - 01/2011
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2012 - 08/2004
1	anti-IgE antibodiesIBA 04/2024
1	Anabolic Androgenic SteroidsIBA 09/2023
1	AndrogensIBA 09/2023
1	Volatile Organic CompoundsIBA 10/2022
1	Leukotriene E4IBA 10/2022
1	Prostaglandin D2IBA 10/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	benralizumabIBA 01/2022
1	reslizumabIBA 01/2022
1	tezepelumabIBA 01/2022
1	ElastinIBA 01/2021
1	Interleukin-33IBA 01/2021
1	FurinIBA 01/2020
1	Phenobarbital (Luminal)FDA Link 11/2019
1	Ribosomal RNAIBA 11/2019
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2019
1	CystatinsIBA 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018
1	RNA IsoformsIBA 01/2018
1	NADPH Oxidases (NAD(P)H oxidase)IBA 12/2017
1	Superoxides (Superoxide)IBA 12/2017
1	Anti-Allergic Agents (Antiallergic Agents)IBA 01/2017
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 07/2016
1	Interleukin-1 (Interleukin 1)IBA 07/2016
1	Phosphotransferases (Kinase)IBA 03/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 03/2016
1	ElementsIBA 01/2016
1	Matrix Metalloproteinases (MMPs)IBA 01/2016
1	Peroxidase (Myeloperoxidase)IBA 01/2016

Therapy/Procedure

14	Therapeutics 11/2022 - 03/2005
2	Biological Therapy 10/2022 - 01/2022
1	Bronchial Thermoplasty 01/2018
1	Lasers (Laser) 01/2016